Immunization with cationized BSA inhibits progression of disease in ApoBec-1/LDL receptor deficient mice with manifest atherosclerosis

Immunobiology

Volumn 216, Issue 6, 2011, Pages 663-669

  Kolbus, Daniel ^a   Wigren, Maria ^a   Ljungcrantz, Irena ^a   Söderberg, Ingrid ^a   Alm, Ragnar ^a   Björkbacka, Harry ^a   Nilsson, Jan ^a   Fredrikson, Gunilla N ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

Author keywords

Apolipoprotein B; Atherosclerosis; Cationized BSA; Immunization; Regulatory T cells

Indexed keywords

ALUMINUM POTASSIUM SULFATE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; BOVINE SERUM ALBUMIN; CHOLESTEROL; COLLAGEN; IMMUNOGLOBULIN G1; LOW DENSITY LIPOPROTEIN RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD3+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EFFECTOR CELL; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; WEIGHT REDUCTION;

EID: 79955528094     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.11.003     Document Type: Article

References (31)

1. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., Merval R., Esposito B., Cohen J.L., Fisson S., Flavell R.A., Hansson G.K., Klatzmann D., Tedgui A., Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 2006, 12:178-180.
2. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., Shaw P.X., Palinski W., Witztum J.L., Silverman G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 2003, 9:736-743.
3. Brånén L., Pettersson L., Lindholm M., Zaina S. A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified. Histochem. J. 2001, 33:227-229.
4. Chang X., Gao J.X., Jiang Q., Wen J., Seifers N., Su L., Godfrey V.L., Zuo T., Zheng P., Liu Y. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J. Exp. Med. 2005, 202:1141-1151.
5. Coligan J.E., Tam J.P., Shao J. Production of antipeptide antisera. Curr. Protoc. Neurosci. 2001, Chapter 5, Unit 5.6.
6. De Groot A.S., Moise L., McMurry J.A., Wambre E., Van Overtvelt L., Moingeon P., Scott D.W., Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide " Tregitopes" Blood 2008, 112:3303-3311.
7. Faria-Neto J.R., Chyu K.Y., Li X., Dimayuga P.C., Ferreira C., Yano J., Cercek B., Shah P.K. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006, 189:83-90.
8. Fredrikson G.N., Anand D.V., Hopkins D., Corder R., Alm R., Bengtsson E., Shah P.K., Lahiri A., Nilsson J. Associations between autoantibodies against apoB-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009, 52:1426-1433.
9. Fredrikson G.N., Hedblad B., Berglund G., Alm R., Ares M., Cercek B., Chyu K.-Y., Shah P.K., Nilsson J. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:872-878.
10. Fredrikson G.N., Schiopu A., Berglund G., Alm R., Shah P., Nilsson J. Autoantibody against the amino acid sequence 661-680 in apoB-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007, 194:e188-e192.
11. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis Annu. Rev. Immunol. 2009, 27:165-197.
12. Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 2006, 1:297-329.
13. Hirano K., Young S.G., Farese R.V., Ng J., Sande E., Warburton C., Powell-Braxton L.M., Davidson N.O. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J. Biol. Chem. 1996, 271:9887-9890.
14. Khallou-Laschet J., Tupin E., Caligiuri G., Poirier B., Thieblemont N., Gaston A.T., Vandaele M., Bleton J., Tchapla A., Kaveri S.V., Rudling M., Nicoletti A. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 2006, 184:330-341.
15. Kono H., Rock K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008, 8:279-289.
16. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205:869-882.
17. Liu Y., Li D., Chen J., Xie J., Bandyopadhyay S., Zhang D., Nemarkommula A.R., Liu H., Mehta J.L., Hermonat P.L. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 2006, 188:19-27.
18. Mallat Z., Ait-Oufella H., Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med. 2007, 17:113-118.
19. Muckerheide A., Apple R.J., Pesce A.J., Michael J.G. Cationization of protein antigens. I. Alteration of immunogenic properties. J. Immunol. 1987, 138:833-837.
20. Muckerheide A., Domen P.L., Michael J.G. Cationization of protein antigens. II. Alteration of regulatory properties. J. Immunol. 1987, 138:2800-2804.
21. Nilsson J., Hansson G.K. Autoimmunity in atherosclerosis: a protective response losing control?. J. Intern. Med. 2008, 263:464-478.
22. Nilsson J., Kovanen P.T. Will autoantibodies help to determine severity and progression of atherosclerosis?. Curr. Opin. Lipidol. 2004, 15:499-503.
23. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:1372-1376.
24. Palinski W., Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J. Intern. Med. 2000, 247:371-380.
25. Schiopu A., Bengtsson J., Soderberg I., Janciauskiene S., Lindgren S., Ares M.P., Shah P.K., Carlsson R., Nilsson J., Fredrikson G.N. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004, 110:2047-2052.
26. Schiopu A., Frendeus B., Jansson B., Soderberg I., Ljungcrantz I., Araya Z., Shah P.K., Carlsson R., Nilsson J., Fredrikson G.N. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J. Am. Coll. Cardiol. 2007, 50:2313-2318.
27. Sjogren P., Fredrikson G.N., Samnegard A., Ericsson C.G., Ohrvik J., Fisher R.M., Nilsson J., Hamsten A. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur. Heart J. 2008, 29:2218-2226.
28. van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks F.M., Illarionov P.A., Besra G.S., Kent S.C., Moody D.B., Brenner M.B. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005, 437:906-910.
29. van Es T., van Puijvelde G.H., Foks A.C., Habets K.L., Bot I., Gilboa E., Van Berkel T.J., Kuiper J. Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. Atherosclerosis 2010, 209:74-80.
30. van Puijvelde G.H., Hauer A.D., de Vos P., van den Heuvel R., van Herwijnen M.J., van der Zee R., van Eden W., van Berkel T.J., Kuiper J. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006, 114:1968-1976.
31. Wigren M., Bengtsson D., Duner P., Olofsson K., Bjorkbacka H., Bengtsson E., Fredrikson G.N., Nilsson J. Atheroprotective effects of alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ. Res. 2009, 104:e62-e70.